TABLE 1.
Characteristics of children with MDR-TB disease or exposure treated with levofloxacina
| Characteristic | Value |
|---|---|
| No. (%) of children of the following ethnicity: | |
| Black | 69 (63.3) |
| Mixed race | 40 (36.7) |
| No. (%) of male children | 56 (51.4) |
| Median (range) age (yr) | 2.1 (0.32–8.65) |
| Median (range) wt (kg) | 12.4 (5.88–21.8) |
| Median (range) wt-for-age Z-score (WHO) | −0.39 (−4.18–3.32)b |
| Median (range) ht-for-age Z-score (WHO) | −1.31 (−4.70–1.45)c |
| Median (range) wt-for-length Z-score (WHO) | 0.60 (−4.88–4.33)d |
| No. (%) of children with the following MDR-TB disease status: | |
| MDR-TB disease (treatment) | 71 (65.1) |
| MDR-TB exposure (preventive therapy) | 38 (34.9) |
| Median (range) levofloxacin total dose (mg) | 212 (88.5–435) |
| Median (range) levofloxacin dose (mg/kg) | 15 (10–21.4) |
| Median (range) creatinine clearance (ml/min)e | 119 (66.6–181) |
| No. (%) of children administered drug by the following procedure: | |
| Whole tablet, orally | 7 (6.4) |
| Crushed tablet, orally | 12 (11) |
| Crushed tablet, nasogastric tube | 90 (82.6) |
| No. (%) of children HIV infected | 16 (14.7) |
a
Data are for 109 children. WHO, World Health Organization.
b
Twelve children had a Z-score of <−2.
c
Thirty-three children had a Z-score of <−2.
d
Two children had a Z-score of <−2.
e
The revised formula of Schwartz et al. (47) was used; the serum creatinine concentration was measured only in the patients treated for TB disease (n = 71, 65.1%).